Mutations in the estrogen receptor are responsible of resistance to standard treatments, and so far no effective alternative drug regimens have been implemented in the clinic. We believe that our proteogenomic workflow can be applied to analyze clinical samples with expressed estrogen receptor mutations to derive alternative drug targets and biomarkers to validate in our model systems and additional clinical cohorts.
Menu